Z-LASIK and Trans-PRK for correction of high-grade myopia: safety, efficacy, predictability and clinical outcomes

Gershoni, Assaf; Livny, Eitan; Bahar, Irit

doi:10.1007/s10792-018-0868-4

Cited by 16 publications

(20 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In our study, the efficacy and safety of both procedures was comparable, and no eyes showed 2 or more lines worse CDVA postoperatively, compared to preoperative CDVA. The postoperative UDVA and CDVA in both groups were acceptable, but when compared with other studies, percentage of UDVA achieving 20/40 or better was 95.4 to 100% in TPRK group [14][15][16] and the percentage was 88.2 to 99% in other FS-LASIK groups [17][18][19][20]. Comparisons of visual outcomes between TPRK and FS-LASIK group in our studies were similar to two others that described treatment for high myopia.…”

Section: Discussionsupporting

confidence: 83%

“…Six eyes were outside ±1.00 D in the FS-LASIK group, where UDVA was decreased. The percentage of eyes within ±0.50D was higher than that in Gershoni's study [20], but lower than that in Aslanides' study [15]. Refractive stability was also better in the TPRK group.…”

Section: Discussioncontrasting

confidence: 58%

“…Gershoni [20] reported that clinical outcomes of FS-LASIK were slightly better than those of TPRK. Another study compared the results of FS-LASIK and PRK for the correction of high myopia and found that FS-LASIK improved UDVA better than PRK [21].…”

Section: Discussionmentioning

confidence: 99%

“…Our efficacy and safety indices in both groups (all more than 1.00) were superior to those of previous studies that corrected myopia. Gershoni [20] reported that efficacy index values were 0.92 in their TPRK group and 0.95 in their FS-LASIK group. Corresponding safety index values were 0.95 and 0.97.…”

Section: Discussionmentioning

confidence: 99%

See 3 more Smart Citations

Comparison of clinical results between trans-PRK and femtosecond LASIK for correction of high myopia

et al. 2020

View full text Add to dashboard Cite

Background: To compare the clinical outcomes of transepithelial photorefractive keratectomy (TPRK) with femtosecond laser-assisted in situ keratomileusis (FS-LASIK) for correction of high myopia. Methods: In this prospective, non-randomised, cohort study, 85 eyes of 46 patients treated with TPRK and 80 eyes of 42 patients treated with FS-LASIK were included. All eyes were highly myopic (spherical equivalent refraction <− 6.00 diopters). Both TPRK and FS-LASIK were performed by Schwind Amaris 750S excimer laser. Visual acuity, refraction, corneal high order aberration (HOA) and other variables were analyzed before and at 1, 3, 6, 12 months after surgery. Results: At 12 months after surgery, uncorrected logMAR distance visual acuity (UDVA) in the TPRK and FS-LASIK groups was − 0.04 ± 0.04 and − 0.01 ± 0.08, respectively (P = 0.039). Corrected logMAR distance visual acuity (CDVA) was − 0.06 ± 0.05 and − 0.04 ± 0.05 in both groups (P = 0.621). For UDVA, 86% of eyes in the TPRK group and 80% in the FS-LASIK group remained unchanged or improved one or more logMAR lines (P = 0.314), compared to preoperative CDVA. For CDVA, 97% of eyes in the TPRK group and 90% in the FS-LASIK group remained unchanged or improved one or more lines (P = 0.096), compared to preoperative CDVA. Spherical equivalent refraction was − 0.05 ± 0.39 and − 0.26 ± 0.47 in both groups (P = 0.030). 87% of eyes in the TPRK group and 73% in the FS-LASIK group achieved ±0.50 D target refraction (P = 0.019). All 85 eyes (100%) in the TPRK group and 75 eyes (92%) in the FS-LASIK group were within ±1.00 D of target (P = 0.003). Root mean square (RMS) of corneal total HOA and vertical coma in the TPRK group were lower compared with the FS-LASIK group (P < 0.001 for both variables). Conclusions: TPRK and FS-LASIK showed good safety, efficacy and predictability for correction of high myopia. Clinical outcomes of TPRK were slightly better than FS-LASIK.

show abstract

Section: Discussionsupporting

confidence: 83%

Section: Discussioncontrasting

confidence: 58%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Comparison of clinical results between trans-PRK and femtosecond LASIK for correction of high myopia

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Our case series resembled the other TransPRK cohorts in terms of preoperative myopia and postoperative UCVA and efficacy and safety indices. Our predictability index (96%) tended to be higher than those of the other TransPRK cohorts (59–87%), possibly because refraction stabilizes at 6–12 months; our study duration was 6 months whereas the studies that reported predictability had durations of 12 months [ 25 , 26 , 28 – 30 , 34 ]. Our low rate of clinically significant haze was also observed by six of the studies (0–1% of patients had Fantes grade ≥2 at the end of follow-up).…”

Section: Discussioncontrasting

confidence: 54%

Efficacy and safety of single-step transepithelial photorefractive keratectomy with the all-surface laser ablation SCHWIND platform without mitomycin-C for high myopia: A retrospective study of 69 eyes

et al. 2021

View full text Add to dashboard Cite

Background Studies suggest that transepithelial photorefractive keratectomy (TransPRK) with the all-surface laser ablation (ASLA)-SCHWIND platform is effective and safe for both low-moderate myopia and high myopia. In most studies, mitomycin-C is administered immediately after surgery to prevent corneal opacification (haze), which is a significant complication of photorefractive keratectomy in general. However, there is evidence that adjuvant mitomycin-C induces endothelial cytotoxicity. Moreover, a recent study showed that omitting adjuvant mitomycin-C did not increase haze in low-moderate myopia. The present case-series study examined the efficacy, safety, and haze rates of eyes with high myopia that underwent ASLA-SCHWIND TransPRK without adjuvant mitomycin-C. Methods All consecutive eyes with high myopia (≤-6 D) that were treated in 2018–2020 with the SCHWIND Amaris 500E® TransPRK excimer laser without adjuvant mitomycin-C in a tertiary-care hospital (France) and were followed up for 6 months were identified. Uncorrected visual acuity (UCVA), best spectacle-corrected visual acuity (BSCVA), and spherical equivalent (SE) were recorded before and after surgery. Postoperative haze was graded using the 4-grade Fantes scale. Efficacy rate (frequency of eyes with 6-month UCVA ≤0.1 logMAR), safety rate (frequency of eyes that lost <2 BSCVA lines), predictability (frequency of eyes with 6-month SE equal to target SE±0.5 D), efficacy index (mean UCVA at 6 months/preoperative BSCVA), and safety index (BSCVA at 6 months/preoperative BSCVA) were computed. Results Sixty-nine eyes (38 patients) were included. Mean preoperative and 6-month SE were -7.44 and -0.05 D, respectively. Mean 6-month UCVA and BSCVA were 0.00 and -0.02 logMAR, respectively. Efficacy rate and index were 95.7% and 1.08, respectively. Safety rate and index were 95.7% and 1.13, respectively. Predictability was 85.5%. Grade 3–4 haze never arose. At 6 months, the haze rate was zero. Conclusions ASLA-SCHWIND TransPRK without mitomycin-C appears to be safe as well as effective and accurate for high myopia.

show abstract

PRK for High Myopia

Santhiago,

Sampaio

2023

Essentials in Ophthalmology

View full text Add to dashboard Cite

Z-LASIK and Trans-PRK for correction of high-grade myopia: safety, efficacy, predictability and clinical outcomes

Cited by 16 publications

References 33 publications

Comparison of clinical results between trans-PRK and femtosecond LASIK for correction of high myopia

Comparison of clinical results between trans-PRK and femtosecond LASIK for correction of high myopia

Efficacy and safety of single-step transepithelial photorefractive keratectomy with the all-surface laser ablation SCHWIND platform without mitomycin-C for high myopia: A retrospective study of 69 eyes

PRK for High Myopia

Contact Info

Product

Resources

About